Frontiers in Immunology (May 2023)

Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses

  • Tim Westphal,
  • Tim Westphal,
  • Maria Mader,
  • Hendrik Karsten,
  • Leon Cords,
  • Maximilian Knapp,
  • Sophia Schulte,
  • Lennart Hermanussen,
  • Sven Peine,
  • Vanessa Ditt,
  • Alba Grifoni,
  • Marylyn Martina Addo,
  • Marylyn Martina Addo,
  • Marylyn Martina Addo,
  • Marylyn Martina Addo,
  • Samuel Huber,
  • Alessandro Sette,
  • Marc Lütgehetmann,
  • Marc Lütgehetmann,
  • Sven Pischke,
  • Sven Pischke,
  • William W. Kwok,
  • John Sidney,
  • Julian Schulze zur Wiesch,
  • Julian Schulze zur Wiesch

DOI
https://doi.org/10.3389/fimmu.2023.1182504
Journal volume & issue
Vol. 14

Abstract

Read online

IntroductionThe nonstructural protein 12 (NSP12) of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has a high sequence identity with common cold coronaviruses (CCC).MethodsHere, we comprehensively assessed the breadth and specificity of the NSP12-specific T-cell response after in vitro T-cell expansion with 185 overlapping 15-mer peptides covering the entire SARS-CoV-2 NSP12 at single-peptide resolution in a cohort of 27 coronavirus disease 2019 (COVID-19) patients. Samples of nine uninfected seronegative individuals, as well as five pre-pandemic controls, were also examined to assess potential cross-reactivity with CCCs.ResultsSurprisingly, there was a comparable breadth of individual NSP12 peptide-specific CD4+ T-cell responses between COVID-19 patients (mean: 12.82 responses; range: 0–25) and seronegative controls including pre-pandemic samples (mean: 12.71 responses; range: 0–21). However, the NSP12-specific T-cell responses detected in acute COVID-19 patients were on average of a higher magnitude. The most frequently detected CD4+ T-cell peptide specificities in COVID-19 patients were aa236–250 (37%) and aa246–260 (44%), whereas the peptide specificities aa686–700 (50%) and aa741–755 (36%), were the most frequently detected in seronegative controls. In CCC-specific peptide-expanded T-cell cultures of seronegative individuals, the corresponding SARS-CoV-2 NSP12 peptide specificities also elicited responses in vitro. However, the NSP12 peptide-specific CD4+ T-cell response repertoire only partially overlapped in patients analyzed longitudinally before and after a SARS-CoV-2 infection.DiscussionThe results of the current study indicate the presence of pre-primed, cross-reactive CCC-specific T-cell responses targeting conserved regions of SARS-CoV-2, but they also underline the complexity of the analysis and the limited understanding of the role of the SARS-CoV-2 specific T-cell response and cross-reactivity with the CCCs.

Keywords